Rossari Biotech Announces Q3 FY26 Results: Revenues Up 13%, EBITDA Up 6%, PAT Up 3%
Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended December 31, 2025. The company reported a 13% YoY growth in revenues, a 6% YoY growth in EBITDA, and a 3% YoY growth in PAT. The Home, Personal Care and Performance Chemicals (HPPC) segment recorded an 11% YoY growth, while the Textile Specialty Chemicals (TSC) segment grew by 18% YoY, and the Animal Health and Nutrition (AHN) segment grew by 39% YoY. The company's international operations also contributed to the growth. However, profitability was impacted by ongoing investments in capacity expansion, product development, and market-seeding initiatives. The company also announced its plan to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA).
Key Highlights
- Q3 FY26 revenues at Rs. 581.7 Cr, up 13% YoY
- EBITDA at Rs. 68.9 Cr, up 6% YoY
- PAT at Rs. 32.8 Cr, up 3% YoY
- HPPC recorded a YoY growth of 11%
- TSC delivered a growth of 18% YoY
- AHN grew by 39% YoY
- Plan to set up greenfield specialty chemicals manufacturing facilities in KSA